

ORIGINAL ARTICLE

Epidemiology, Genetics & Prevention

WILEY

Prenatal high molecular weight phthalates and bisphenol A, and childhood respiratory and allergic outcomes

Kimberly Berger¹ | Brenda Eskenazi¹ | John Balmes¹ | Katie Kogut¹ | Nina Holland¹ |
Antonia M. Calafat² | Kim G. Harley¹

¹Center for Environmental Research and Children's Health (CERCH), School of Public Health, University of California, Berkeley, Berkeley, California

²Division of Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, Georgia

Correspondence

Kim G. Harley, Center for Environmental Research and Children's Health (CERCH), School of Public Health, University of California, Berkeley, Berkeley, CA.
Email: kharley@berkeley.edu

Funding information

U.S. Environmental Protection Agency, Grant/Award Number: R82670901 and RD83171001; National Institute for Environmental Health Sciences, Grant/Award Number: 1RC2 ES018792, P01 ES009605, R01 ES021369, R21 ES024909 and R24 ES028529; Environmental Protection Agency

Edited by: Ömer Kalayci

Abstract

Background: The prevalence of asthma and allergy is increasing in US children. In utero exposure to chemicals used in personal care products and plastics may contribute to increase in these diseases.

Methods: We quantified urinary concentrations of eight phthalate metabolites and bisphenol A in mothers twice during pregnancy in 1999-2000 in Salinas, California. We assessed probable asthma, aeroallergies, eczema, and spirometry in their children at age 7, and measured T helper 1 and T helper 2 cells in blood at ages 2, 5, and 7 (N = 392). We employed Bayesian model averaging to select confounders from additional biomarkers measured in this population and controlled for them in logistic and linear regressions.

Results: Monocarboxyisooctyl phthalate was associated with increased odds for probable asthma (odds ratio: 1.54, 95% CI: 1.12, 2.12), and with lower forced expiratory volume in one second (β : -0.09 L, 95% CI: -0.15, -0.03) and forced expiratory flow from 25% to 75% of forced vital capacity (β : -7.06 L/s, 95% CI: -11.04, -2.90). Several other associations were attenuated in final models that controlled for additional biomarkers.

Conclusion: Monocarboxyisooctyl phthalate was associated with lower respiratory health after controlling for related chemical exposure, which suggests that confounding by multiple chemical exposures should be considered in future research.

KEYWORDS

Asthma, bisphenol A, diethylhexyl phthalate, endocrine disruptor, environmental exposure, hypersensitivity, Th1-Th2 balance

1 | INTRODUCTION

Rates of childhood asthma, aeroallergy, and eczema have increased substantially since the 1960s and have plateaued since the 1990s.^{1,2} Currently, in the United States 8.3%-15.9% of children are estimated to have asthma,^{3,4} 24.6% to have aeroallergies,⁵ and 14.3% to have eczema.⁵ Respiratory infections, dietary deficiencies, damp or moldy housing, air conditioning, and increased hygiene have all been associated with increases in asthma or inhalant allergies in recent decades.^{6,7} Environmental chemicals may also be contributing

to increases in these diseases. Air pollution, environmental tobacco smoke, heavy metals, and pesticides have been hypothesized as affecting asthma or inhalant allergies.⁶⁻¹¹ Studies in animals and humans suggest that exposure to certain environmental chemicals found in plastics, such as high molecular weight (HMW) phthalates and bisphenol A (BPA), may also be responsible for some of the increased incidence of disease.^{12,13} Benzyl butyl phthalate (BBzP), di-isononyl phthalate (DiNP), di-isodecyl phthalate (DiDP), and di(2-ethylhexyl) phthalate (DEHP) are widely used as plasticizers in food packages, building materials, medical devices, vinyl flooring, and

paints. BPA, used in polycarbonate plastics, can be found in certain food and beverage packaging, dental sealants, and receipts. BPA and most HMW phthalate metabolites were detected in $\geq 90\%$ of Americans in 2013-2014.¹⁴

Animal studies on these chemicals suggest associations between decreased lung function,¹⁵ dermatitis,¹⁶ and an increased T helper 2 (Th2) cell response.¹⁷ Several longitudinal epidemiologic studies conducted in New York City, Ohio, Sweden, Spain, and Bulgaria reported associations between HMW phthalates and BPA and asthma or respiratory symptoms, aeroallergy, and eczema,¹² but results have conflicted on cytokines,¹² which may play a role in asthma and allergy development.^{18,19} T helper 1 (Th1) cells release cytokines such as γ -interferon (IFN- γ), interleukin-2 (IL-2), and IL-3 and act through cell-mediated immunity to attack intracellular viruses and bacteria. Th2 cells release cytokines such as IL-4, IL-5, and IL-6 and are involved in allergic and inflammatory immunity.²⁰ A higher ratio of Th2 cytokines to Th1 cytokines has been associated with increased risks of aeroallergy and asthma.^{18,19} Further research on this topic would enhance the epidemiologic literature on plasticizing chemicals and atopy.

Plasticizing chemicals can cross the placental barrier,^{21,22} and prenatal exposures may have greater impact on immune system functioning than later exposures.²³ We measured urinary concentrations of eight phthalate metabolites and BPA at two time points during pregnancy. Our primary objective was to analyze associations of prenatal HMW phthalate and BPA biomarkers with asthma, aeroallergies, eczema, and lung function at age 7, and our secondary objective was to analyze associations with T helper 1 (Th1) and Th2 cell percentages in whole blood at ages 2, 5, and 7. This is the first study to examine associations between in utero concentrations of these biomarkers and cytokine levels in childhood, and one of the first studies to examine atopic illnesses and cytokine levels in the same study.

2 | METHODS

2.1 | Study population

The Center for the Health Assessment of Mothers and Children of Salinas (CHAMACOS) has followed children living in the Salinas Valley, California, from birth to age 16.²⁴ Women attending first prenatal care visits at local clinics were screened for eligibility in 1999-2000. Women were invited to participate if they spoke Spanish or English, were ≤ 20 weeks' pregnant, were ≥ 18 years old, qualified for MediCal (low-income health insurance), and planned to deliver at the county hospital. Participant mothers were primarily Mexican-born, Spanish-speaking, and lived with or were farmworkers. Of the 601 women enrolled, 531 were followed through a live birth. Of these, 517 children had at least one prenatal HMW phthalate or BPA measurement (101 children each was missing both prenatal samples for MBzP, MCNP, MCOP, and MCPP, and metabolites for DEHP, and 27 children were missing

both prenatal samples for BPA). Of the 517 children with at least one prenatal biomarker measurement, 167 were missing data on probable asthma; 180 were missing data on aeroallergies; 181 were missing data on eczema; 219 did not have measurements for FEV₁; 249 each did not have measurements for FVC, FEV₁/FVC, or FEF_{25%-75%}; and 281, 288, and 265 did not have cytokines measurements at ages 2, 5, and 7, respectively. There were 392 children with data on at least one prenatal biomarker and one outcome. This study conforms to recognized ethical standards and was approved by the Office for the Protection of Human Subjects (OPHS) at UC Berkeley. The Centers for Disease Control and Prevention (CDC) deferred to the OPHS. Mothers gave written informed consent, and children verbally assented at age 7.

2.2 | Questionnaire data collection

Mothers completed interviewer-administered, structured questionnaires in English or Spanish twice during pregnancy, at delivery, and when children were 6 months old and 1, 2, 3.5, 5, and 7 years old. During the first pregnancy interview, questionnaires asked about maternal age, education, country of birth, years lived in the United States, parity, family income, and family history of asthma (mother, father, or siblings).

2.3 | Exposure assessment

Mothers provided spot urine samples at two interviews during pregnancy (first interview: mean 13 weeks' gestation, range 5-27; second interview: mean 26 weeks' gestation, range 21-40). Phthalate- and BPA-free polypropylene urine cups were used to collect urine, which was aliquoted into glass vials and stored at -80°C until shipment to the CDC.

We used solid phase extraction coupled with isotope dilution high-performance liquid chromatography-tandem mass spectrometry to quantify BPA and eight phthalate metabolites: monobenzyl phthalate (MBzP) [a metabolite of BBzP]; four metabolites of DEHP [mono-2-ethylhexyl phthalate, mono-(2-ethyl-5-hydroxyhexyl) phthalate, mono-(2-ethyl-5-oxohexyl) phthalate, and mono-(2-ethyl-5-carboxypentyl) phthalate]; mono(carboxyoctyl) phthalate (MCOP; a metabolite of DiNP); mono(carboxynonyl) phthalate (MCNP) [a metabolite of DiDP]; and mono(3-carboxypropyl) phthalate (MCPP) [a metabolite of several HMW phthalates and a minor metabolite of dibutyl phthalate]. Analytic methods have been published previously for phthalates²⁵ and BPA.²⁶ Concentrations were reported in ng/mL of urine, and limits of detection ranged from 0.2 to 0.5 ng/mL. Concentrations below the limits of detection were assigned the instrument-reading values, if available, or an imputed value below the limits of detection selected randomly from the log-normal distribution using maximum likelihood estimation.²⁷ We combined mono-2-ethylhexyl phthalate, mono-(2-ethyl-5-hydroxyhexyl) phthalate, mono-(2-ethyl-5-oxohexyl) phthalate, and mono-(2-ethyl-5-carboxypentyl) phthalate to create a molar sum of DEHP metabolites (ΣDEHP).

A handheld refractometer (National Instrument Company Inc, Baltimore, Maryland) was used to measure urinary specific gravity. We imputed urinary specific gravity based on urinary creatinine for 81 samples missing specific gravity measurements by regressing specific gravity on creatinine and multiplying the coefficient by existing creatinine values to generate missing specific gravity values. We used the formula $(\text{analyte concentration} \times (1.024 - 1)) / (\text{sample specific gravity} - 1)$ to correct for urinary dilution.²⁸

2.4 | Outcome Assessment

The primary outcomes for this study were probable asthma, aeroallergies, and eczema at age 7, and lung function at age 7. We defined "probable asthma" at age 7 as currently taking asthma medication or having two or more of the following criteria: any current respiratory symptom, doctor diagnosis of asthma at any age, or a positive bronchodilator test. A child was considered to have been diagnosed with asthma if the mother had reported a doctor's diagnosis at any visit, and to have respiratory symptoms at age 7 if mothers reported any of the following based on the International Study of Asthma and Allergies in Childhood questionnaire²⁹: tightness in the chest and difficulty breathing; wheezing or whistling in the chest; trouble sleeping, speaking, running, or playing because of wheezing, whistling, shortness of breath, or coughing without a cold; or an asthma attack. Mothers were also asked if their child was currently taking asthma medication. Spirometry was administered at age 7 using three identical EasyOne spirometers that were calibrated daily. Children performed up to eight expiratory maneuvers, lasting at least three seconds. Two physicians with experience in pediatric spirometry verified all maneuvers, and the best verified maneuver was used for analyses. Forced expiratory volume in one second (FEV₁), forced vital capacity (FVC), FEV₁/FVC, and forced expiratory flow from 25% to 75% of FVC (FEF_{25%-75%}) were measured from each maneuver.

Children whose mothers reported they had respiratory symptoms at age 7 (*n* = 54) were offered a bronchodilator test, for which they inhaled albuterol and repeated spirometry 20 minutes later. A positive test was defined as 12%+ improvement from their best FEV₁ or FVC before the bronchodilator.

A child was considered to have eczema at age 7 if the mother reported a doctor's diagnosis of "eczema or an allergic skin rash" in the last year, and a child was considered to have aeroallergies if the mother reported "runny or itchy eyes apart from colds," "sneezing or a runny nose apart from colds," or a doctor's diagnosis of "hay fever or allergic rhinitis" in the last year.

2.5 | Cytokine detection

A secondary outcome of this study was the percentage of Th1 and Th2 cytokine-producing cells, and their ratio. Flow cytometry was used to detect Th1 and Th2 cells in unfrozen pediatric whole blood collected at ages 2, 5, and 7. Methods have been previously described.³⁰ We divided the number of Th1 and Th2 cells by the total number of CD4+ cells to obtain the percentage of Th1 and Th2

(Th1% and Th2%) cells, respectively. Th1:Th2 cell ratio was defined as Th1% divided by Th2%.

2.6 | Statistical analysis

We averaged urinary biomarker concentrations across pregnancy and used specific gravity-corrected values in all analyses. We analyzed the first and second biomarker measurements separately in sensitivity analyses. Biomarker concentrations were examined as continuous log₂-transformed variables. In initial analyses, separate models were constructed for each biomarker; subsequent analyses included several biomarkers in the same model to explore confounding.

Probable asthma, aeroallergies, and eczema were analyzed as binary variables using logistic regression, and lung function and Th1 and Th2 levels were analyzed as continuous variables using linear regression or generalized estimating equations. FEV₁ and FVC were

TABLE 1 Demographic characteristics of the study population: CHAMACOS children in Salinas, California (1999-2008)

Characteristics at time of pregnancy	N (%)
Maternal age	
18-24	174 (44.7)
25-29	123 (31.6)
30-34	62 (15.9)
35+	30 (7.7)
Household income as a proportion of poverty	
<100%	240 (61.2)
>100%	152 (38.8)
Maternal education	
6th grade or less	174 (44.7)
7th-12th grade	136 (35.0)
High school graduate or greater	79 (20.3)
Maternal country of birth	
United States	48 (12.3)
Mexico	334 (85.9)
Other	7 (1.8)
Years mother has lived in the United States	
Five or fewer	195 (50.1)
Six to ten	96 (24.7)
Eleven or more	101 (26.0)
Parity	
First child	126 (32.4)
Second child	117 (30.1)
Third child or greater	146 (37.5)
Child's mother, father, or siblings have asthma history	
No	354 (90.3)
Yes	38 (9.7)

CHAMACOS, Center for the Health Assessment of Mothers and Children of Salinas.

not transformed; FEV_1/FVC , $FEF_{25\%-75\%}$, Th1%, Th2%, and Th1:Th2 cell ratio were assessed as continuous $\log_{10}$ -transformed variables. Thus, for each twofold increase in biomarker concentration, regression coefficients represent mean or percent difference in outcomes. To determine the longitudinal association of cytokine variables at ages 2, 5, and 7, we used generalized estimating equations with Gaussian specification and an exchangeable correlation structure, including interaction terms for child age.

In demographically adjusted models, we included maternal age at birth, parity, household income as a proportion of poverty at baseline, and family history of asthma as confounders, as determined a priori via directed acyclic graphs. We then generated fully adjusted models controlling for additional chemical exposure. In addition to the HMW phthalates and BPA discussed in this paper, we aimed to control for metabolites of low molecular weight phthalates (monoethyl phthalate, mono-n-butyl phthalate, mono-isobutyl phthalate) and phenols (methyl paraben, propyl paraben, triclosan, 2,4-dichlorophenol, 2,5-dichlorophenol, benzophenone-3) that were measured in the same urine samples. To identify the most important variables to include, we used Bayesian model averaging (BMA),³¹ which estimates models for all possible combinations of the specified biomarkers with an outcome, and weights models by their posterior model probability while adjusting for demographic covariates to determine how influential given variables are on an outcome. BMA produces posterior inclusion probabilities, which are measurements of each variable's influence on the outcome relative to other variables in the BMA model. We conducted BMA and chose the three most influential variables (those with the highest posterior inclusion probabilities) to include in fully adjusted regression models for each outcome.

We conducted generalized additive models (GAMs) for all associations to test for linearity of relationships. We controlled for the same covariates as in fully adjusted models and allowed for three

equivalent degrees of freedom. Relationships were considered linear if the P-value was above 0.05.

BMA analyses were conducted in R³² (Vienna, Austria) with the BMS package.³³ Descriptive statistics and regressions were conducted in Stata 14 (College Station, TX).

3 | RESULTS

Most mothers were aged 18-29 at enrollment (76%), lived below 100% of the federal poverty index (61%), and were multiparous (68%); most children had no family history of asthma (90%) (Table 1). All plasticizer biomarkers were detected in over 90% of urine samples (Table 2). Correlations ranged as high as 0.73 (MCNP and MCOP) (Figure 1).

We categorized 37 children (11%) with probable asthma, 87 children (25%) with aeroallergies, and 23 children (7%) with eczema (Table 3). Th1:Th2 cell ratios and Th1% increased as children aged, while Th2% stayed stable with age (Table 3).

The posterior inclusion probabilities for each outcome are shown in Table S1. The top three ranked biomarkers were MCOP, propyl paraben, and 2,4-dichlorophenol for probable asthma; MCP, BPA, and MCOP for aeroallergies; MCP, mono-isobutyl phthalate, and mono-n-butyl phthalate for eczema; MCOP, mono-n-butyl phthalate, and monoethyl phthalate for FEV_1 ; MCOP, MCNP, and monoethyl phthalate for FVC; MBzP, MCOP, and BPA for FEV_1/FVC ; MCOP, monoethyl phthalate, and triclosan for $FEF_{25\%-75\%}$; mono-isobutyl phthalate, triclosan, and mono-n-butyl phthalate for Th1:Th2 ratio; methyl paraben, 2,4-dichlorophenol, and propyl paraben for Th1%; and mono-n-butyl phthalate, methyl paraben, and monoethyl phthalate for Th2%.

Table 4 shows prenatal maternal urinary MCOP concentrations were associated with increased odds for probable asthma in fully

TABLE 2 Distribution of specific gravity-corrected phthalate monoester metabolites and BPA in CHAMACOS maternal prenatal urine collected at two time points in pregnancy in Salinas, California (1999-2000)

Biomarker	LOD	%>LOD		Average of two measurements						
		Early Pregnancy ^a (%)	Late Pregnancy ^b (%)	Geo. Mean	10th%	25th%	50th%	75th%	90th%	95th%
MBzP (ng/mL)	0.3	98.3	98.9	8.9	2.5	4.9	9.2	17.7	28.3	40.1
MCNP (ng/mL)	0.2	97.5	97.4	2.3	1.0	1.5	2.3	3.4	5.2	7.6
MCOP (ng/mL)	0.2	97.0	96.8	3.8	1.5	2.4	3.9	5.5	8.7	11.6
MCP (ng/mL)	0.2	90.3	95.1	2.2	0.8	1.4	2.4	3.8	5.1	7.1
Σ DEHP (μ mol/mL)	0.2-0.5 ^d	97.0 ^c	97.0 ^c	0.2	0.1	0.1	0.2	0.4	0.6	0.8
BPA (μ g/mL)	0.4	97.4	97.8	1.5	0.6	0.9	1.3	2.2	3.7	5.8

BPA: bisphenol A; CHAMACOS: Center for the Health Assessment of Mothers and Children of Salinas; DEHP: di(2-ethylhexyl) phthalate; LOD: limit of detection; MBzP: monobenzyl phthalate; MCNP: mono(carboxynonyl) phthalate; MCOP: monocarboxyisooctyl phthalate; MCP: mono(3-carboxypropyl) phthalate; MEHP: mono(2-ethylhexyl) phthalate; OR: odds ratio.

^aMean = 13 weeks' gestation.

^bMean = 26 weeks' gestation.

^cMEHP used as proxy for Σ DEHP in %>LOD.

^dLODs for metabolites of DEHP were 0.5 for MEHP and 0.2 for MEHHP, MEOHP, and MECCP.




FIGURE 1 Correlations of log2 specific gravity-corrected phthalate, paraben, and other phenol urinary concentrations of CHAMACOS mothers during pregnancy (* $P < 0.05$) [Colour figure can be viewed at wileyonlinelibrary.com]

adjusted models (OR: 1.54, 95% CI: 1.12, 2.12) and increased odds for aeroallergies in demographically adjusted models (OR: 1.28, 95% CI: 1.01, 1.61). BPA (OR: 1.34, 95% CI: 1.04, 1.71) and MCPP (OR: 1.35, 95% CI: 1.06, 1.72) concentrations were associated with increased odds for aeroallergies in demographically adjusted models. MBzP also showed an association with aeroallergies in fully adjusted models, and MCNP concentrations showed associations with increased odds for probable asthma and aeroallergies in demographically adjusted models. There were no associations with eczema.

Table 5 shows associations between urinary biomarker concentrations and spirometry measures. For each twofold increase in biomarker concentration, regression coefficients represent mean (FEV₁ and FVC) or percent difference (FEV₁/FVC and FEF_{25%-75%}) in

outcomes. MCOP concentrations were associated with lower FEV₁ (β : -0.09 L, 95% CI: -0.15, -0.03) and FEF_{25%-75%} (percent difference: -7.06 L/s, 95% CI: -11.04, -2.90) in fully adjusted models, and with lower FVC (β : -0.07 liters, 95% CI: -0.13, 0.00) in demographically adjusted models. MCNP concentrations also showed associations with lower FEV₁ (β : -0.05 liters, 95% CI: -0.11, 0.01) and lower FEF_{25%-75%} (percent difference: -5.29 liters/second, 95% CI: -9.74, -0.61) in demographically adjusted models. MBzP concentrations also showed associations with lower FEV₁ (β : -0.04 liters, 95% CI: -0.09, 0.00) and lower FEF_{25%-75%} (percent difference: -4.23 liters/second, 95% CI: -7.72, -0.60) in demographically adjusted models.

Table S2 shows no associations in generalized estimating equation models of cytokines across ages 2, 5, and 7, with P -values for

TABLE 3 Respiratory symptom, spirometry, and cytokine data in CHAMACOS participants in Salinas, California (2006-2008)

Maternal report		N (%)
Probable asthma ^a		37 (11%)
Any current symptoms		54 (15%)
Any current asthma medication use		22 (6%)
Past diagnosis of asthma		62 (18%)
Positive bronchodilator test ^b		10 (3%)
Aeroallergy symptoms or diagnosis		87 (25%)
Eczema diagnosis		23 (7%)
		N
		Mean (standard deviation)
Spirometry		
Best maneuver (all children)		
FEV ₁	300	1.8 (0.5) L
FVC	270	2.1 (0.6) L
FEV ₁ /FVC	270	0.9 (0.1)
FEF ₂₅₋₇₅	270	2.5 (0.9) L/s
Cytokine variable		
Age 2		
Th1:Th2 cell ratio	239	6.13 (5.58)
% CD4 cells	239	32.9 (7.5)
% Th1 cells	239	4.0 (3.0)
% Th2 cells	239	0.9 (0.7)
Age 5		
Th1:Th2 cell ratio	231	14.40 (44.53)
% CD4 cells	231	29.9 (7.3)
% of Th1 cells	231	6.8 (3.2)
% of Th2 cells	231	1.1 (0.8)
Age 7		
Th1:Th2 cell ratio	254	22.51 (36.29)
% CD4 cells	254	33.8 (10.2)
% of Th1 cells	254	10.0 (5.9)
% of Th2 cells	254	0.9 (0.7)

CHAMACOS, Center for the Health Assessment of Mothers and Children of Salinas; FEF_{25%-75%}, forced expiratory flow from 25% to 75% of forced vital capacity; FEV₁, lower forced expiratory volume in one second; FVC, forced vital capacity; SD, standard deviation.

^aDefined as: currently taking asthma medications or any two of current respiratory symptoms, diagnosis of asthma, positive bronchodilator test.

^bCompleted only by children with respiratory symptoms (N = 42).

interaction by age. For each twofold increase in biomarker concentration, regression coefficients in this table represent percent difference in outcomes.

Table S3 shows the results of GAM analyses testing for linearity. All associations demonstrate linear relationships.

Sensitivity analyses examining the first and second biomarker measurements separately yielded results similar to the main models with averaged values (data not shown). Correlations ranged from 0.29 for MBzP to 0.16 for MCOP.

4 | DISCUSSION

We found that prenatal urinary concentrations of MCOP were associated with increased odds for probable asthma and with lower lung function at age 7, after controlling for demographic factors and related chemical exposures, and were associated with increased odds for aeroallergies in demographically adjusted models. MCNP concentrations were associated with increased odds for probable asthma and aeroallergies and with lower lung function in demographically adjusted models. MBzP concentrations were associated with lower lung function, and MCP and BPA concentrations were associated with increased odds for aeroallergies in demographically adjusted models.

Previous studies of chemical exposures and respiratory and allergic outcomes have examined one biomarker at a time, failing to account for multiple exposures. We used BMA variable selection to identify potentially confounding biomarkers to control for, and results from these fully adjusted models showed markedly fewer associations than models adjusted for demographic confounders only. When estimates were higher in fully adjusted models compared to demographically adjusted models, such as with MCOP and probable asthma, we believe this indicates reduced confounding by the presence of other related chemical biomarkers. Results from demographically adjusted models resemble those from other studies to a greater extent than do our fully adjusted models, suggesting that other studies' findings may be partially due to confounding by co-exposure to other chemicals.

Our strongest findings were with MCOP, a phthalate metabolite on which there have been few studies. Our results agree with the Dampness in Buildings and Health study that observed an association between living with polyvinyl chloride flooring, which may be a source of exposure to the parent compounds of MCOP and MCP, at ages 1-3, and increased risk of asthma and aeroallergies, but not eczema, at ages 6-8.³⁴ Our results also agree with the cross-sectional associations found between MCOP, MCNP, and MCP and asthma in participants aged 18 and over in the 2005-2006 NHANES study.³⁵ However, a French birth cohort study found no association between prenatal urinary concentrations of these chemicals and asthma or FEV₁ at age 5.³⁶

Our study found many null associations, which could indicate a true lack of association or low power to detect associations due to low sample size. Specifically, unlike several other studies,¹² we did not find associations of in utero exposures to DEHP, BBzP, or BPA and probable asthma or allergy risk. One of these studies reported associations with early childhood but not in utero BPA,³⁷ which suggests that early childhood exposure to BPA may be more impactful on childhood lung health and may explain our null results.

Our study found little evidence of associations of prenatal maternal urinary concentrations of metabolites of HMW phthalates or BPA with Th1 and Th2 profiles in childhood. No other studies have examined the effect of these plasticizing chemicals on Th1 and Th2 function in childhood, and only a small number have examined prenatal exposure and cytokine function in cord blood. One study

TABLE 4 Association of Log 2 prenatal urinary biomarker concentrations and asthma outcomes in CHAMACOS children in Salinas, California (1999–2008)

Biomarker	Probable asthma								
	Crude			Demographically adjusted ^a			Fully adjusted ^b		
	N	OR	95% CI	N	OR	95% CI	N	OR	95% CI
MBzP	336	0.99	0.77, 1.29	333	1.05	0.79, 1.38	329	0.88	0.63, 1.24
MCNP	336	1.34	0.98, 1.84	333	1.38	0.97, 1.97	329	1.21	0.71, 2.06
MCOP	336	1.37	1.04, 1.80	333	1.42	1.03, 1.94	329	1.54	1.12, 2.12
MCPP	336	1.24	0.91, 1.70	333	1.30	0.92, 1.85	329	1.15	0.75, 1.74
ΣDEHP	336	0.99	0.72, 1.36	333	1.02	0.73, 1.43	329	0.81	0.53, 1.23
BPA	346	1.04	0.75, 1.45	343	1.19	0.83, 1.71	329	1.03	0.68, 1.55
	Aeroallergies								
	Crude			Demographically adjusted ^a			Fully adjusted ^c		
	N	OR	95% CI	N	OR	95% CI	N	OR	95% CI
MBzP	327	1.01	0.84, 1.21	324	1.03	0.85, 1.25	321	0.81	0.63, 1.04
MCNP	327	1.24	0.98, 1.56	324	1.25	0.98, 1.61	321	1.01	0.70, 1.44
MCOP	327	1.22	0.99, 1.52	324	1.28	1.01, 1.61	321	1.09	0.82, 1.45
MCPP	327	1.30	1.04, 1.64	324	1.35	1.06, 1.72	321	1.20	0.90, 1.61
ΣDEHP	327	1.07	0.85, 1.34	324	1.12	0.89, 1.42	321	0.91	0.68, 1.21
BPA	334	1.24	0.99, 1.56	331	1.34	1.04, 1.71	321	1.19	0.91, 1.57
	Eczema								
	Crude			Demographically adjusted ^a			Fully adjusted ^d		
	N	OR	95% CI	N	OR	95% CI	N	OR	95% CI
MBzP	326	0.98	0.71, 1.36	323	1.00	0.72, 1.40	323	1.34	0.86, 2.09
MCNP	326	0.91	0.60, 1.39	323	0.94	0.61, 1.45	323	1.17	0.70, 1.96
MCOP	326	0.99	0.68, 1.46	323	1.03	0.69, 1.55	323	1.39	0.87, 2.20
MCPP	326	0.79	0.58, 1.07	323	0.77	0.56, 1.07	323	0.83	0.57, 1.21
ΣDEHP	326	0.96	0.64, 1.44	323	0.96	0.64, 1.45	323	1.25	0.79, 1.98
BPA	333	0.86	0.56, 1.31	330	0.89	0.57, 1.39	320	1.00	0.61, 1.63

BPA, bisphenol A; CHAMACOS, Center for the Health Assessment of Mothers and Children of Salinas; CI, confidence interval; DEHP, di(2-ethylhexyl) phthalate; MBzP, monobenzyl phthalate; MCNP, mono(carboxynonyl) phthalate; MCOP, monocarboxyisooctyl phthalate; MCPP, mono(3-carboxypropyl) phthalate; OR, odds ratio.

Separate models created for each chemical.

^aModels control for maternal age, parity, household income as a proportion of poverty at baseline, child's family history of asthma, and maternal education.

^bModels control for maternal age, parity, household income as a proportion of poverty at baseline, child's family history of asthma, maternal education, monocarboxyisooctyl phthalate, propyl paraben, 2,4-dichlorophenol.

^cModels control for maternal age, parity, household income as a proportion of poverty at baseline, child's family history of asthma, maternal education, mono(3-carboxypropyl) phthalate, bisphenol A, monocarboxyisooctyl phthalate.

^dModels control for maternal age, parity, household income as a proportion of poverty at baseline, child's family history of asthma, maternal education, mono(3-carboxypropyl) phthalate, mono-isobutyl phthalate, mono-n-butyl phthalate.

found no association between prenatal maternal urinary concentrations of or BPA and cord blood Th2 cytokine concentrations in infants³⁸, while another found an association between prenatal maternal blood concentrations of BPA and higher Th2 cytokines in cord blood³⁹. However, T helper cell-related immunity changes drastically from birth to age 2⁴⁰, and these previous studies may not be appropriate comparisons.

One limitation of our study is that although the focus of this paper was atopic illnesses, some of our probable asthma cases may be non-atopic and our inability to differentiate atopic versus non-atopic cases obscures any differentiation by etiology. Our population is from a largely low-income Mexican-American farm working community, and may not be comparable to other study populations. Our sample size was also relatively small, which may have resulted

TABLE 5 Association of Log 2 prenatal urinary biomarker concentrations and spirometry outcomes in CHAMACOS children in Salinas, California (1999-2008)

FEV ₁									
Biomarker	Crude			Demographically adjusted ^a			Fully adjusted ^b		
	N	β	95% CI	N	β	95% CI	N	β	95% CI
MBzP	290	-0.04	-0.08, 0.00	287	-0.04	-0.09, 0.00	287	-0.03	-0.09, 0.03
MCNP	290	-0.05	-0.11, 0.00	287	-0.05	-0.11, 0.01	287	0.00	-0.07, 0.08
MCOP	290	-0.07	-0.12, -0.02	287	-0.07	-0.12, -0.02	287	-0.09	-0.15, -0.03
MCPD	290	-0.04	-0.08, 0.01	287	-0.04	-0.08, 0.01	287	-0.02	-0.08, 0.04
ΣDEHP	290	0.00	-0.05, 0.05	287	0.00	-0.05, 0.06	287	0.03	-0.03, 0.10
BPA	296	-0.02	-0.07, 0.04	293	-0.02	-0.07, 0.04	285	0.00	-0.06, 0.06
FVC									
Crude	Demographically adjusted ^a			Fully adjusted ^c					
	N	β	95% CI	N	β	95% CI	N	β	95% CI
MBzP	260	-0.02	-0.07, 0.03	257	-0.02	-0.08, 0.03	257	0.02	-0.05, 0.08
MCNP	260	-0.05	-0.12, 0.01	257	-0.05	-0.12, 0.02	257	-0.01	-0.10, 0.09
MCOP	260	-0.07	-0.12, -0.01	257	-0.07	-0.13, 0.00	257	-0.06	-0.14, 0.03
MCPD	260	-0.02	-0.08, 0.03	257	-0.03	-0.08, 0.03	257	0.01	-0.06, 0.08
ΣDEHP	260	-0.01	-0.07, 0.05	257	-0.01	-0.07, 0.06	257	0.04	-0.04, 0.11
BPA	266	-0.03	-0.09, 0.03	263	-0.04	-0.11, 0.02	255	-0.01	-0.08, 0.06
FEV1/FVC									
Crude	Demographically adjusted ^a			Fully adjusted ^d					
	N	Diff.	95% CI	N	Diff.	95% CI	N	Diff.	95% CI
MBzP	260	-0.42	-1.05, 0.22	257	-0.37	-1.02, 0.29	255	-0.42	-1.19, 0.35
MCNP	260	-0.35	-1.16, 0.46	257	-0.20	-1.05, 0.65	255	-0.01	-1.16, 1.16
MCOP	260	-0.48	-1.21, 0.25	257	-0.36	-1.15, 0.43	255	-0.35	-1.27, 0.58
MCPD	260	-0.16	-0.83, 0.51	257	-0.08	-0.77, 0.61	255	0.09	-0.76, 0.93
ΣDEHP	260	0.06	-0.70, 0.83	257	0.10	-0.68, 0.88	255	0.35	-0.58, 1.29
BPA	266	0.45	-0.32, 1.23	263	0.47	-0.34, 1.28	255	0.73	-0.15, 1.61

(Continues)

TABLE 5 (Continued)

FEF25%-75%									
Crude			Demographically adjusted ^a			Fully adjusted ^e			
N	Diff.	95% CI	N	Diff.	95% CI	N	Diff.	95% CI	
MBzP	-0.42	-1.05, 0.22	257	-0.37	-1.02, 0.29	255	-0.42	-1.19, 0.35	
MCNP	-0.35	-1.16, 0.46	257	-0.20	-1.05, 0.65	255	-0.01	-1.16, 1.16	
MCOP	-0.48	-1.21, 0.25	257	-0.36	-1.15, 0.43	255	-0.35	-1.27, 0.58	
MCPP	-0.16	-0.83, 0.51	257	-0.08	-0.77, 0.61	255	0.09	-0.76, 0.93	
ΣDEHP	0.06	-0.70, 0.83	257	0.10	-0.68, 0.88	255	0.35	-0.58, 1.29	
BPA	0.45	-0.32, 1.23	263	0.47	-0.34, 1.28	255	0.73	-0.15, 1.61	

BPA, bisphenol A; CHAMACOS, Center for the Health Assessment of Mothers and Children of Salinas; CI, confidence interval; DEHP, di(2-ethylhexyl) phthalate; MBzP, monobenzyl phthalate; MCNP, mono(carboxynonyl) phthalate; MCOP, monocarboxyisooctyl phthalate; MCPP, mono(3-carboxypropyl) phthalate; Diff, difference.

Separate models created for each chemical.

^aModels control for maternal age, parity, household income as a proportion of poverty at baseline, child's family history of asthma, and maternal education.

^bModels control for maternal age, parity, household income as a proportion of poverty at baseline, child's family history of asthma, maternal education, monocarboxyisooctyl phthalate, mono-n-butyl phthalate, monoethyl phthalate.

^cModels control for maternal age, parity, household income as a proportion of poverty at baseline, child's family history of asthma, maternal education, monocarboxyisooctyl phthalate, monocarboxyisononyl phthalate, monoethyl phthalate.

^dModels control for maternal age, parity, household income as a proportion of poverty at baseline, child's family history of asthma, maternal education, monobenzyl phthalate, monocarboxyisooctyl phthalate, bisphenol A.

^eModels control for maternal age, parity, household income as a proportion of poverty at baseline, child's family history of asthma, maternal education, monocarboxyisooctyl phthalate, monoethyl phthalate, triclosan.

in lower power to detect differences. Additionally, as in all studies, type I and type II errors may have occurred. Our employment of BMA as a variable selection tool is a strength, though it should be noted that BMA does not adequately account for collinearity among variables. Although few of our included biomarkers were highly correlated, many are used in similar products and this is not corrected for in BMA. Intraclass correlation coefficients (ICCs) for these chemicals are generally low in our population (high molecular weight phthalates range from 0.14 to 0.37 and the ICC for BPA is 0.16), indicating high variability between samples. However, unlike many previous studies, our exposure estimates are based on two measures of urinary chemical concentrations during pregnancy rather than one. Our urinary biomarker measurements at two prenatal time points are also a strength because gestational exposure to environmental chemicals may influence lung development and function more substantially than later exposures.⁴¹ Our comprehensive evaluation of atopic diseases in childhood is also a strength. We measured cytokine levels at several ages, spanning important periods in juvenile immune system development, and we measured lung function. We used an integrated classification of probable asthma based on a number of asthma-related variables, including bronchodilator responsiveness. However, while our probable asthma and aeroallergy case definitions were based on both symptoms and medical management, we were unable to apply the same rigor to our eczema cases, which were based only on maternal report of a doctor diagnosis of eczema in their children.

We observed that prenatal maternal urinary concentrations of biomarkers of exposure to HMW phthalates, particularly MCOP, a metabolite of DiNP, are associated with increased odds of probable asthma and aeroallergies at age 7, and with lower lung function at age 7. The potential clinical relevance of the slightly lower lung function of the exposed children is difficult to assess at one time point, but reduced lung function in childhood has been associated with lower lung function and increased risk of respiratory illness in adulthood. We found limited evidence that prenatal urinary concentrations of BPA are associated with increased odds of aeroallergies at age 7, and did not confirm findings of other studies that showed associations between BPA and respiratory symptoms. This is the first study to examine the relationship between prenatal maternal urinary concentrations of any high molecular weight phthalate or BPA and cytokine measurements in childhood. It is also one of the first studies to evaluate associations between in utero exposures to MCOP, MCNP, or MCP and childhood asthma, aeroallergies, or eczema, and one of the first studies to analyze atopic illnesses and cytokines concurrently. Future research should measure IgE in children along with asthma status in order to distinguish atopic versus non-atopic asthma and any associations with prenatal chemical exposure that are differential by this distinction. In addition, other classes of CD4+ cells such as Th17 cells and regulatory T cells should be evaluated for their associations with prenatal exposure to the chemicals in this study to further characterize the behavior of the childhood immune system in conjunction with these chemicals.

ACKNOWLEDGEMENTS

We would like to acknowledge Xiaoyun Ye, Manori Silva, and Tao Jia for their work on biomarker measurement, and Eric Coker for his counsel on Bayesian model averaging methods. This work was supported by the Environmental Protection Agency (grants R82670901, RD83171001) and the National Institute for Environmental Health Sciences (grants P01 ES009605, 1RC2 ES018792, R01 ES021369, R21 ES024909, R24 ES028529).

DISCLAIMER

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. Use of trade names is for identification only and does not imply endorsement by the Centers for Disease Control and Prevention, the Public Health Service, or the US Department of Health and Human Services.

CONFLICT OF INTEREST

The authors declare no conflict of interests.

AUTHOR CONTRIBUTIONS

Drs. Eskenazi, Harley, and Holland designed and conducted the study. Ms. Kogut managed and conducted the study. Dr. Holland analyzed the blood samples for cytokines and maintained the biorepository for blood and urine samples. Dr. Calafat analyzed the urine samples for biomarker concentrations. Dr. Balme reviewed the spirometry maneuvers and consulted on respiratory variables and case definitions. Dr. Berger analyzed the data and wrote the manuscript. All authors provided critical review of the manuscript.

REFERENCES

1. Akinbami LJ, Moorman JE, Garbe PL, Sondik EJ. Status of childhood asthma in the United States, 1980-2007. *Pediatrics*. 2009;123(Supplement 3):S131-S145.
2. Jackson KD, Howie LD, Akinbami OJ. Trends in allergic conditions among children: United States, 1997-2011. 2013.
3. CDC. National Health and Nutrition Examination Survey Data. US Department of Health and Human Services. 2013-2014.
4. CDC. National Current Asthma Prevalence (2016). Most Recent Asthma Data. 2018.
5. CDC. National Health and Nutrition Examination Survey Data. US Department of Health and Human Services. 2005-2006.
6. Dick S, Friend A, Dynes K, et al. A systematic review of associations between environmental exposures and development of asthma in children aged up to 9 years. *BMJ open*. 2014;4(11):e006554.
7. Ebert CS, Pillsbury HC. Epidemiology of allergy. *Otolaryngol Clin North Am*. 2011;44(3):537-548.
8. Huang S-K, Zhang Q, Qiu Z, Chung KF. Mechanistic impact of outdoor air pollution on asthma and allergic diseases. *J Thorac Dis*. 2015;7(1):23.
9. Patelarou E, Tzanakis N, Kelly FJ. Exposure to indoor pollutants and wheeze and asthma development during early childhood.

- International journal of environmental research and public health*. 2015;12(4):3993-4017.
10. Yang S-N, Hsieh C-C, Kuo H-F, et al. The effects of environmental toxins on allergic inflammation. *Allergy, asthma & immunology research*. 2014;6(6):478-484.
 11. Yoo Y, Perzanowski MS. Allergic sensitization and the environment: latest update. *Curr Allergy Asthma Rep*. 2014;14(10):1-9.
 12. Robinson L, Miller R. The impact of bisphenol A and phthalates on allergy, asthma, and immune function: a review of latest findings. *Current Environmental Health Reports*. 2015;2(4):379-387.
 13. Savage JH, Matsui EC, Wood RA, Keet CA. Urinary levels of triclosan and parabens are associated with aeroallergen and food sensitization. *J Allergy Clin Immunol*. 2012;130(2):pp. 453-460 e457.
 14. CDC. Fourth Report on Human Exposure to Environmental Chemicals, Updated Tables (March, 2018). Atlanta, GA, USA: Department of Health and Human Services, Centers for Disease Control and Prevention. 2018.
 15. Nakajima Y, Goldblum RM, Midoro-Horiuti T. Fetal exposure to bisphenol A as a risk factor for the development of childhood asthma: an animal model study. *Environmental Health*. 2012;11(1):8.
 16. Shen S, Li J, You H, et al. Oral exposure to diisodecyl phthalate aggravates allergic dermatitis by oxidative stress and enhancement of thymic stromal lymphopoietin. *Food Chem Toxicol*. 2017;99:60-69.
 17. Yan H, Takamoto M, Sugane K. Exposure to bisphenol A prenatally or in adulthood promotes TH2 cytokine production associated with reduction of CD4⁺ CD25⁺ Regulatory T Cells. *Environ Health Perspect*. 2008;116(4):514.
 18. Barnes PJ. Th2 cytokines and asthma: an introduction. *Respir Res*. 2001;2(2):64-65.
 19. Deo SS, Mistry KJ, Kakade AM, Niphadkar PV. Role played by Th2 type cytokines in IgE mediated allergy and asthma. *Lung India: Official Organ of Indian Chest Society*. 2010;27(2):66.
 20. Volcheck GW. Overview of the Human Immune Response. *Clinical Allergy*. Springer. 2008;1-39.
 21. Balakrishnan B, Henare K, Thorstensen EB, Ponnampalam AP, Mitchell MD. Transfer of bisphenol A across the human placenta. *Am J Obstet Gynecol*. 2010;202(4):393.e1-393.e7.
 22. Mose T, Mortensen GK, Hedegaard M, Knudsen LE. Phthalate monoesters in perfusate from a dual placenta perfusion system, the placenta tissue and umbilical cord blood. *Reprod Toxicol*. 2007;23(1):83-91.
 23. Holladay SD, Smialowicz RJ. Development of the murine and human immune system: differential effects of immunotoxicants depend on time of exposure. *Environ Health Perspect*. 2000;108(Suppl 3):463.
 24. Eskenazi B, Bradman A, Gladstone EA, Jaramillo S, Birch K, Holland NT. CHAMACOS, A longitudinal birth cohort study: lessons from the fields. *Journal of Children's Health*. 2003;1(1):3-27.
 25. Silva M, Preau JL Jr, Reidy JA, Needham LL, Calafat AM. Quantification of 22 phthalate metabolites in human urine. *J Chromatogr*. 2007;860:106-112.
 26. Ye X, Kuklenyik Z, Needham LL, Calafat AM. Automated on-line column-switching HPLC-MS/MS method with peak focusing for the determination of nine environmental phenols in urine. *Anal Chem*. 2005;77(16):5407-5413.
 27. Lubin JH, Colt JS, Camann D, et al. Epidemiologic evaluation of measurement data in the presence of detection limits. *Environ Health Perspect*. 2004;112(17):1691-1696.
 28. Cone EJ, Caplan YH, Moser F, Robert T, Shelby MK, Black DL. Normalization of urinary drug concentrations with specific gravity and creatinine. *J Anal Toxicol*. 2009;33(1):1-7.
 29. Asher MI, Keil U, Anderson HR, et al. International Study of Asthma and Allergies in Childhood (ISAAC): rationale and methods. *Eur Respir J*. 1995;8(3):483-491.
 30. Duramad P, McMahon CW, Hubbard A, Eskenazi B, Holland NT. Flow cytometric detection of intracellular TH1/TH2 cytokines using whole blood: validation of immunologic biomarker for use in epidemiologic studies. *Cancer Epidemiol Biomarkers Prev*. 2004;13(9):1452-1458.
 31. Madigan D, Raftery AE, Volinsky C, Hoeting J Bayesian model averaging. Paper presented at: Proceedings of the AAAI Workshop on Integrating Multiple Learned Models, Portland, OR, 1996.
 32. Team RC. R: *Language and Environment for Statistical Computing*. R Foundation for Statistical Computing, Vienna, Austria, 2013.
 33. Zeugner S Bayesian model averaging with BMS. *Tutorial to the R-package*. BMS. 1e30. 2011.
 34. Larsson M, Hägerhed-Engman L, Kolarik B, et al. PVC-as flooring material-and its association with incident asthma in a Swedish child cohort study. *Indoor Air*. 2010;20(6):494-501.
 35. Strassle PD, Smit LA, Hoppin JA. Endotoxin enhances respiratory effects of phthalates in adults: Results from NHANES 2005-6. *Environ Res*. 2018;162:280-286.
 36. Vernet C, Pin I, Giorgis-Allemand L, et al. In utero exposure to select phenols and phthalates and respiratory health in five-year-old boys: a prospective study. *Environ Health Perspect*. 2017;125(9):097006.
 37. Donohue KM, Miller RL, Perzanowski MS, et al. Prenatal and postnatal bisphenol A exposure and asthma development among inner-city children. *Journal of Allergy and Clinical Immunology*. 2013;131(3):pp. 736-742. e736.
 38. Ashley-Martin J, et al. Prenatal exposure to phthalates, bisphenol A and perfluoroalkyl substances and cord blood levels of IgE, TSLP and IL-33. *Environmental research*. 2015;140:360-368.
 39. Liao S-L, et al. Prenatal exposure to bisphenol-A is associated with Toll-like receptor-induced cytokine suppression in neonates. *Pediatric research*. 2016;79(3):438.
 40. Smart, JM and Kemp, AS. Ontogeny of T-helper 1 and T-helper 2 cytokine production in childhood. *Pediatric allergy and immunology*, 2001;12(4):181-187.
 41. Duijts L. Fetal and infant origins of asthma. *Eur J Epidemiol*. 2012;27(1):5-14.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of the article.

How to cite this article: Berger K, Eskenazi B, Balmes J, et al. Prenatal high molecular weight phthalates and bisphenol A, and childhood respiratory and allergic outcomes. *Pediatr Allergy Immunol*. 2019;30:36–46. <https://doi.org/10.1111/pai.12992>

Supplementary Tables for “Prenatal high molecular weight phthalates and bisphenol A, and childhood respiratory and allergic outcomes”

Authors: Kimberly Berger, Brenda Eskenazi, John Balmes, Katie Kogut, Nina Holland, Antonia M. Calafat, Kim G. Harley

Supplementary Table S1. Posterior Inclusion Probabilities for All Phthalate Metabolites, Parabens, and Other Phenols Included in Bayesian Model Averaging in CHAMACOS Children in Salinas, California (1999-2008)

Supplemental Table S2. Longitudinal Association of Log 2 Prenatal Urinary Biomarker Concentrations and Th Cell Parameters at Various Ages, with P-values for Age Interaction, in CHAMACOS Children in Salinas, California (1999-2008)

Supplementary Table S3. P-values for Nonlinearity from Generalized Additive Models of Log 2 Prenatal Urinary Biomarker Concentrations and Outcomes in CHAMACOS Children in Salinas, California (1999-2008)

Supplementary Table S1. Posterior Inclusion Probabilities for All Phthalate Metabolites, Parabens, and Other Phenols Included in Bayesian Model Averaging in CHAMACOS Children in Salinas, California (1999-2008)

Probable asthma		Aeroallergy		Eczema	
Biomarker	PIP	Biomarker	PIP	Biomarker	PIP
MCOP	0.49632	MCPP	0.3852	MCPP	0.14364
PP	0.34866	BPA	0.1997	MiBP	0.11838
2,4-DCP	0.3064	MCOP	0.18	MBP	0.10278
2,5-DCP	0.28932	MCNP	0.12806	TCS	0.09872
MCNP	0.22588	MEP	0.08354	PP	0.06064
TCS	0.13788	BP3	0.07486	BPA	0.0606
MEP	0.09948	MP	0.06488	MCOP	0.06032
MCPP	0.0898	2,5-DCP	0.06398	DEHP	0.05962
DEHP	0.0837	DEHP	0.06302	2,5-DCP	0.05946
MBzP	0.08046	MBP	0.06074	MBzP	0.0586
MP	0.07366	2,4-DCP	0.05966	2,4-DCP	0.05596
MBP	0.05968	MBzP	0.05696	BP3	0.05556
MiBP	0.05786	MiBP	0.0512	MCNP	0.0542
BPA	0.0551	PP	0.05082	MP	0.05392
BP3	0.0541	TCS	0.04946	MEP	0.04824

FEV ₁		FVC		FEV ₁ /FVC		FEF _{25-75%}	
Biomarker	PIP	Biomarker	PIP	Biomarker	PIP	Biomarker	PIP
MCOP	0.66466	MCOP	0.35496	MBzP	0.11956	MCOP	0.86484
MBP	0.2935	MCNP	0.14798	MCOP	0.11138	MEP	0.47884
MEP	0.20016	MEP	0.1376	BPA	0.09802	TCS	0.25894
TCS	0.16676	2,4-DCP	0.12026	MBP	0.09102	MBP	0.21654
MBzP	0.16286	MBP	0.11434	MEP	0.09082	MiBP	0.13526
DEHP	0.12568	MiBP	0.11052	MiBP	0.07946	MCNP	0.10418
MiBP	0.11768	MP	0.08536	MCNP	0.07818	MP	0.10216
MCNP	0.11484	TCS	0.08512	2,5-DCP	0.07084	MBzP	0.10176
2,4-DCP	0.09038	2,5-DCP	0.07386	TCS	0.06952	BPA	0.0839
MCPP	0.08704	MBzP	0.07226	2,4-DCP	0.06356	DEHP	0.07692
PP	0.0822	BP3	0.07112	DEHP	0.06158	PP	0.07322
2,5-DCP	0.06896	BPA	0.06872	PP	0.05902	MCPP	0.0726
MP	0.06412	MCPP	0.068	MCPP	0.05802	2,5-DCP	0.0724
BP3	0.06256	PP	0.0568	MP	0.05726	2,4-DCP	0.06906
BPA	0.05618	DEHP	0.05664	BP3	0.05534	BP3	0.05946

Th1:Th2 cell ratio, longitudinal		Th1 %, longitudinal		Th2 %, longitudinal	
----------------------------------	--	---------------------	--	---------------------	--

Biomarker	PIP	Biomarker	PIP	Biomarker	PIP
MiBP	0.50792	MP	0.23526	MBP	0.49648
TCS	0.11874	2,4-DCP	0.18488	MP	0.46472
MBP	0.10796	PP	0.14144	MEP	0.1533
MEP	0.10054	2,5-DCP	0.12154	MiBP	0.10566
MBzP	0.06234	MiBP	0.10412	TCS	0.09864
PP	0.05944	BP3	0.07546	DEHP	0.07348
2,4-DCP	0.05644	DEHP	0.06732	2,5-DCP	0.06194
2,5-DCP	0.05028	MBzP	0.04716	PP	0.05894
MCNP	0.04946	MCOP	0.04706	2,4-DCP	0.04618
MCPP	0.04538	MBP	0.04492	BP3	0.0438
BP3	0.04534	MEP	0.04248	MCPP	0.0431
MP	0.04096	TCS	0.03784	MCNP	0.04226
MCOP	0.0394	MCNP	0.03674	BPA	0.04042
DEHP	0.03828	MCPP	0.03418	MBzP	0.03922
BPA	0.03714	BPA	0.03194	MCOP	0.03324

2,4-DCP: 2,4-Dichlorophenol; 2,5-DCP: 2,5-Dichlorophenol; BP3: Benzophenone-3; BPA: Bisphenol A; CHAMACOS: Center for the Health Assessment of Mothers and Children of Salinas; DEHP: Di(2-ethylhexyl) phthalate; FEF25-75%: Forced expiratory flow from 25–75% of forced vital capacity; FEV1: Lower forced expiratory volume in one second; FVC: Forced vital capacity; MBP: mono-n-butyl phthalate; MBzP: Monobenzyl phthalate; MCNP: Mono(carboxynonyl) phthalate; MCOP: Monocarboxyisooctyl phthalate; MCPP: Mono(3-carboxypropyl) phthalate; MEP: monoethyl phthalate; MiBP: mono-isobutyl phthalate; MP: Methyl paraben; PIP: Posterior Inclusion Probabilities; PP: Propyl paraben; Th1: T helper 1; Th2: T helper 2; TCS: Triclosan

Supplemental Table S2. Longitudinal Association of Log 2 Prenatal Urinary Biomarker Concentrations and Th Cell Parameters at Various Ages, with P-values for Age Interaction, in CHAMACOS Children in Salinas, California (1999-2008)

Th1:Th2 cell ratio										
Biomarker	Crude			Demographically adjusted [†]			Fully adjusted [‡]			p-int
	N	Percent difference	95% CI	N	Percent difference	95% CI	N	Percent difference	95% CI	
MBzP	34 1	-1.21	-7.14, 5.09	338	-0.06	-6.34, 6.65	335	5.74	-1.29, 13.28	0.25
MCNP	34 1	-2.52	-8.43, 3.77	338	-0.50	-6.84, 6.27	335	1.17	-5.72, 8.57	0.72
MCOP	34 1	-2.31	-7.70, 3.40	338	-0.18	-6.08, 6.09	335	3.22	-3.70, 10.64	0.85
MCP	34 1	-3.45	-9.56, 3.07	338	-2.61	-8.88, 4.10	335	0.70	-6.46, 8.40	0.89
ΣDEHP	34 1	-1.88	-7.44, 4.00	338	-4.37	-10.13, 1.76	335	-0.95	-7.84, 6.47	0.22
BPA	36 2	-3.46	-10.28, 3.88	359	-2.45	-9.56, 5.21	335	-0.73	-8.18, 7.33	0.42
Th1%										
	Crude			Demographically adjusted [†]			Fully adjusted [§]			p-int
	N	Percent difference	95% CI	N	Percent difference	95% CI	N	Percent difference	95% CI	
MBzP	34 1	1.40	-2.87, 5.87	338	1.63	-2.81, 6.26	335	1.96	-2.40, 6.53	0.73
MCNP	34 1	-1.37	-6.10, 3.59	338	-0.68	-5.82, 4.74	335	-0.13	-5.36, 5.40	0.29
MCOP	34 1	0.64	-3.34, 4.78	338	1.18	-3.22, 5.78	335	1.07	-3.36, 5.70	0.46
MCP	34 1	-1.44	-5.90, 3.23	338	-1.06	-5.70, 3.81	335	-0.79	-5.45, 4.10	0.16
ΣDEHP	34 1	-2.14	-7.01, 3.00	338	-4.46	-9.52, 0.89	335	-4.68	-9.63, 0.55	0.81
BPA	36 2	-0.36	-5.76, 5.36	359	-0.21	-5.82, 5.74	359	-0.66	-6.21, 5.22	0.44
Th2%										
Crude			Demographically adjusted [†]			Fully adjusted [¶]				

	N	Percent difference	95% CI	N	Percent difference	95% CI	N	Percent difference	95% CI	p- int
MBzP	1	2.76	-2.77, 8.60	338	1.78	-4.05, 7.95	335	-0.19	-6.15, 6.15	0.10
MCNP	1	1.19	-4.84, 7.61	338	-0.19	-6.54, 6.58	335	-0.95	-7.57, 6.14	0.90
MCOP	1	2.81	-2.87, 8.82	338	1.12	-5.04, 7.67	335	-1.62	-7.83, 5.00	0.83
MCPP	1	1.94	-4.69, 9.02	338	1.43	-5.24, 8.57	335	-0.54	-7.31, 6.73	0.20
ΣDEHP	1	-0.42	-6.44, 5.98	338	-0.25	-6.02, 5.87	335	-3.91	-10.35, 3.00	0.42
BPA	2	3.30	-3.42, 10.50	359	2.35	-4.61, 9.81	335	0.71	-6.42, 8.38	0.75

BPA: Bisphenol A; CHAMACOS: Center for the Health Assessment of Mothers and Children of Salinas; CI: Confidence Interval; DEHP: Di(2-ethylhexyl) phthalate; MBzP: Monobenzyl phthalate; MCNP: Mono(carboxynonyl) phthalate; MCOP: Monocarboxyisooctyl phthalate; MCPP: Mono(3-carboxypropyl) phthalate; Th1: T helper 1; Th2: T helper 2;

Separate models created for each chemical

†Models control for maternal age, parity, household income as a proportion of poverty at baseline, child's family history of asthma, and maternal education

‡Models control for maternal age, parity, household income as a proportion of poverty at baseline, child's family history of asthma, maternal education, mono-isobutyl phthalate, mono-n-butyl phthalate, triclosan

§Models control for maternal age, parity, household income as a proportion of poverty at baseline, child's family history of asthma, maternal education, methyl paraben, 2,4-dichlorophenol, propyl paraben

¶Models control for maternal age, parity, household income as a proportion of poverty at baseline, child's family history of asthma, maternal education, mono-n-butyl phthalate, methyl paraben, monoethyl phthalate

Supplementary Table S3. P-values for Nonlinearity from Generalized Additive Models of Log 2 Prenatal Urinary Biomarker Concentrations and Outcomes in CHAMACOS Children in Salinas, California (1999-2008)

Biomarker	P-value		
	Probable Asthma	Aeroallergy	Eczema
MBzP	0.09	0.36	0.24
MCNP	0.19	0.27	0.13
MCOP	0.47	0.59	0.31
MCP	0.60	0.46	0.21
Σ DEHP	0.33	0.27	0.53
BPA	0.66	0.07	0.10

	P-value			
	FEV ₁	FVC	FEV ₁ /FVC	FEF _{25-75%}
MBzP	0.46	0.49	0.22	0.53
MCNP	0.22	0.18	0.58	0.42
MCOP	0.46	0.31	0.31	0.35
MCP	0.65	0.58	0.20	0.69
Σ DEHP	0.32	0.34	0.07	0.07
BPA	0.73	0.50	0.35	0.55

	P-value		
	Th1:Th2 cell ratio	Th1%	Th2%
MBzP	0.54	0.52	0.34
MCNP	0.35	0.24	0.46
MCOP	0.67	0.68	0.77
MCP	0.33	0.62	0.08
Σ DEHP	0.49	0.07	0.29
BPA	0.56	0.70	0.37

BPA: Bisphenol A; CHAMACOS: Center for the Health Assessment of Mothers and Children of Salinas; CI: Confidence Interval; DEHP: Di(2-ethylhexyl) phthalate; MBzP: Monobenzyl phthalate; MCNP: Mono(carboxynonyl) phthalate; MCOP:

Monocarboxyisooctyl phthalate; MCPP: Mono(3-carboxypropyl) phthalate; OR: Odds ratio

Separate models created for each chemical

See Tables 4, 5, and Supplementary Table S2 for covariates specific to each outcome